• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

包含肿瘤微坏死的新型模型的开发与验证,用于预测肝细胞癌患者的术后生存情况

Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients with Hepatocellular Carcinoma.

作者信息

Sun Xuqi, Wang Yangyang, Ge Hongbin, Chen Cao, Han Xu, Sun Ke, Wang Meng, Wei Xiaobao, Ye Mao, Zhang Qi, Liang Tingbo

机构信息

Department of Medical Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

出版信息

J Hepatocell Carcinoma. 2023 Jul 25;10:1181-1194. doi: 10.2147/JHC.S423687. eCollection 2023.

DOI:10.2147/JHC.S423687
PMID:37521028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10386864/
Abstract

BACKGROUND

The heterogeneity of hepatocellular carcinoma (HCC) leads to the unsatisfying predictive performance of current staging systems. HCC patients with pathological tumor micronecrosis have an immunosuppressive microenvironment. We aimed to develop novel prognostic models by integrating micronecrosis to predict the survival of HCC patients after hepatectomy more precisely.

METHODS

We enrolled 765 HCC patients receiving curative hepatic resection. They were randomly divided into a training cohort (n= 536) and a validation cohort (n = 229). We developed two prognostic models for postoperative recurrence-free survival (RFS) and overall survival (OS) based on independent factors identified through multivariate Cox regression analyses. The predictive performance was assessed using the Harrell concordance index (C-index) and the time-dependent area under the receiver operating characteristic curve, compared with six conventional staging systems.

RESULTS

The RFS and OS nomograms were developed based on tumor micronecrosis, tumor size, albumin-bilirubin grade, tumor number and prothrombin time. The C-indexes for the RFS nomogram and OS nomogram were respectively 0.66 (95% CI, 0.62-0.69) and 0.74 (95% CI, 0.69-0.79) in the training cohort, which was significantly better than those of the six common staging systems (0.52-0.61 for RFS and 0.53-0.63 for OS). The results were further confirmed in the validation group, with the C-indexes being 0.66 and 0.77 for the RFS and OS nomograms, respectively.

CONCLUSION

The two nomograms could more accurately predict RFS and OS in HCC patients receiving curative hepatic resection, thereby aiding in formulating personalized postoperative follow-up plans.

摘要

背景

肝细胞癌(HCC)的异质性导致当前分期系统的预测性能不尽人意。伴有病理肿瘤微坏死的HCC患者具有免疫抑制微环境。我们旨在通过整合微坏死来开发新的预后模型,以更准确地预测HCC患者肝切除术后的生存情况。

方法

我们纳入了765例行根治性肝切除术的HCC患者。他们被随机分为训练队列(n = 536)和验证队列(n = 229)。我们基于多因素Cox回归分析确定的独立因素,开发了两个用于预测术后无复发生存期(RFS)和总生存期(OS)的预后模型。与六个传统分期系统相比,使用Harrell一致性指数(C指数)和受试者操作特征曲线下的时间依赖性面积评估预测性能。

结果

基于肿瘤微坏死、肿瘤大小、白蛋白-胆红素分级、肿瘤数量和凝血酶原时间,开发了RFS和OS列线图。训练队列中,RFS列线图和OS列线图的C指数分别为0.66(95%CI,0.62 - 0.69)和0.74(95%CI,0.69 - 0.79),显著优于六个常见分期系统(RFS为0.52 - 0.61,OS为0.53 - 0.63)。在验证组中结果得到进一步证实,RFS和OS列线图的C指数分别为0.66和0.77。

结论

这两个列线图可以更准确地预测接受根治性肝切除术的HCC患者的RFS和OS,从而有助于制定个性化的术后随访计划。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/a840c9f4a42d/JHC-10-1181-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/7e6321c581ce/JHC-10-1181-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/06d998c0a04a/JHC-10-1181-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/33d4866a9bae/JHC-10-1181-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/beede91f9358/JHC-10-1181-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/a840c9f4a42d/JHC-10-1181-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/7e6321c581ce/JHC-10-1181-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/06d998c0a04a/JHC-10-1181-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/33d4866a9bae/JHC-10-1181-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/beede91f9358/JHC-10-1181-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b9/10386864/a840c9f4a42d/JHC-10-1181-g0005.jpg

相似文献

1
Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients with Hepatocellular Carcinoma.包含肿瘤微坏死的新型模型的开发与验证,用于预测肝细胞癌患者的术后生存情况
J Hepatocell Carcinoma. 2023 Jul 25;10:1181-1194. doi: 10.2147/JHC.S423687. eCollection 2023.
2
Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection.纳入CNLC分期系统的列线图可预测肝细胞癌根治性切除术后的预后。
Front Oncol. 2022 Jan 21;11:755920. doi: 10.3389/fonc.2021.755920. eCollection 2021.
3
Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus.新型模型预测乙型肝炎病毒相关≤10cm 单发肝细胞癌且无门静脉癌栓患者的术后复发和总生存期。
Oncologist. 2020 Oct;25(10):e1552-e1561. doi: 10.1634/theoncologist.2019-0766. Epub 2020 Aug 6.
4
Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma.开发并验证一种包含不同血管模式的模型,以评估肝癌患者的生存情况。
JAMA Netw Open. 2021 Sep 1;4(9):e2125055. doi: 10.1001/jamanetworkopen.2021.25055.
5
Prognostic value and association of sarcopenic obesity and systemic inflammatory indexes in patients with hepatocellular carcinoma following hepatectomy and the establishment of novel predictive nomograms.肝切除术后肝细胞癌患者中肌肉减少性肥胖与全身炎症指标的预后价值及相关性分析与新型预测列线图的建立
J Gastrointest Oncol. 2021 Apr;12(2):669-693. doi: 10.21037/jgo-20-341.
6
Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers.基于炎症标志物的肝癌肝切除术后预后列线图的开发与验证
J Hepatocell Carcinoma. 2022 Dec 29;9:1403-1413. doi: 10.2147/JHC.S390858. eCollection 2022.
7
A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma.一种预测肝细胞癌无复发生存率和总生存率的新型列线图模型。
Front Oncol. 2022 Jul 22;12:946531. doi: 10.3389/fonc.2022.946531. eCollection 2022.
8
Novel inflammation-based prognostic nomograms for individualized prediction in hepatocellular carcinoma after radical resection.基于新型炎症的预后列线图在肝细胞癌根治性切除术后个体化预测中的应用
Ann Transl Med. 2020 Sep;8(17):1061. doi: 10.21037/atm-20-1919.
9
Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection.根治性切除术后单个大肝癌和巨大肝癌的预后列线图的建立和验证。
Eur J Cancer. 2021 Sep;155:85-96. doi: 10.1016/j.ejca.2021.07.009. Epub 2021 Aug 6.
10
Simplified nomograms based on platelet-associated models for survival prediction in Asian hepatocellular carcinoma patients after surgery.基于血小板相关模型的简化列线图用于预测亚洲肝细胞癌患者术后的生存情况。
Surg Oncol. 2019 Sep;30:131-138. doi: 10.1016/j.suronc.2019.07.008. Epub 2019 Jul 22.

本文引用的文献

1
Evaluation of Lactate Dehydrogenase and Alkaline Phosphatase as Predictive Biomarkers in the Prognosis of Hepatocellular Carcinoma and Development of a New Nomogram.评估乳酸脱氢酶和碱性磷酸酶作为肝细胞癌预后预测生物标志物及构建新的列线图
J Hepatocell Carcinoma. 2023 Jan 14;10:69-79. doi: 10.2147/JHC.S398632. eCollection 2023.
2
PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.PD-1 抑制剂联合抗血管生成治疗联合或不联合强度调制放疗治疗晚期肝细胞癌:一项倾向评分匹配研究。
Front Immunol. 2022 Sep 23;13:972503. doi: 10.3389/fimmu.2022.972503. eCollection 2022.
3
Histological tumor micronecrosis in resected specimens after R0 hepatectomy for hepatocellular carcinomas is a factor in determining adjuvant TACE: A retrospective propensity score-matched study.
RO 肝切除术后标本中肿瘤组织的微观坏死是决定辅助 TACE 的因素:一项回顾性倾向评分匹配研究。
Int J Surg. 2022 Sep;105:106852. doi: 10.1016/j.ijsu.2022.106852. Epub 2022 Aug 24.
4
PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma.循环肿瘤细胞上的程序性死亡受体配体1(PD-L1)表达可能是晚期肝细胞癌中程序性死亡受体1(PD-1)抑制剂联合放疗及抗血管生成治疗的预测生物标志物。
Front Oncol. 2022 Aug 2;12:873830. doi: 10.3389/fonc.2022.873830. eCollection 2022.
5
Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study.热休克蛋白 90α 是肝细胞癌有潜力的预后和预测生物标志物:一项大规模多中心研究。
Hepatol Int. 2022 Oct;16(5):1208-1219. doi: 10.1007/s12072-022-10391-y. Epub 2022 Aug 16.
6
Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.伽玛刀放射外科与经导管动脉化疗栓塞治疗合并门静脉癌栓的肝细胞癌:一项倾向评分匹配研究。
Hepatol Int. 2022 Aug;16(4):858-867. doi: 10.1007/s12072-022-10339-2. Epub 2022 Jun 21.
7
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.新开发的改良ALBI分级对肝细胞癌显示出更好的预后和预测价值。
Liver Cancer. 2021 Dec 8;11(1):1-8. doi: 10.1159/000521374. eCollection 2022 Jan.
8
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐:2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
9
The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria.白蛋白-胆红素评分与凝血酶原时间相结合是预测 Child-Pugh A 级肝细胞癌患者经动脉化疗栓塞术后肝功能障碍的有用工具,纳入标准最多为七条。
J Clin Med. 2021 Oct 21;10(21):4838. doi: 10.3390/jcm10214838.
10
Method of Tumor Pathological Micronecrosis Quantification Via Deep Learning From Label Fuzzy Proportions.基于深度学习从模糊标签比例量化肿瘤病理微坏死的方法。
IEEE J Biomed Health Inform. 2021 Sep;25(9):3288-3299. doi: 10.1109/JBHI.2021.3071276. Epub 2021 Sep 3.